TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05261412

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Consent
Description: Participants in the control arm will undergo Standard Consent which will consist of paper PIL provided by EIDO healthcare followed by a verbal discussion (standardized by following a checklist of topics to discuss) with the responsible consultant surgeon and signing of the consent form. The time taken to read the PIL (self-recorded by the patient) will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital health education tool (dHET)
Description: Participants randomized to the intervention dHET will receive the dHET followed by a verbal discussion (as above) and signing of the consent form. The dHET will be delivered on a tablet computer and facilitated by a research assistant who will ensure all technological issues are overcome but will not engage with the participant with regard facilitating better understanding of the content. The digital offering will be interactive; participants will be able to traverse through each section at their own pace with the ability to re-visit sections. It also contains a two-minute narrated animation of the procedure, which can played, rewinded or fast forward. The time spent reading each section of the dHET and time spent watching the animation will be recorded. The time spent with the responsible surgeon will also be recorded, as will the number of questions asked by the participant.
Study: NCT04845490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin
Description: Mitomycin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Mitomycin 30mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin
Description: Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Lobaplatin 50mg/m2. Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
Study: NCT06251999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fospropofol sedation
Description: Fospropofol sedation for same-day bidirectional endoscopy in elderly patients

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: propofol
Study: NCT05518474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-proning
Description: Rotating between lying flat with the chest down, on one's side or sitting up every 30 minutes to 2 hours when lying down during the day or while sleeping at night.
Study: NCT06282211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Oral Soluble Pellicles
Description: patients applying cisplatin-based chemotherapy regimen were treated with the triple combination of fosaprepitant (Tanneng, Jiangsu Haosen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone for the prophylaxis of nausea and vomiting prior to the chemotherapy, and were divided into the experimental group and the control group by whether or not to continue the prophylaxis with o Ondansetron Oral Soluble Pellicles for 5-7 days after the chemotherapy as shown in the figure below.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ondansetron Oral Soluble Pellicles
Description: patients applying cisplatin-based chemotherapy regimen were treated with the triple combination of fosaprepitant (Tanneng, Jiangsu Haosen Pharmaceutical Group Co., Ltd.) + Ondansetron Oral Soluble Pellicles (Aiqisu, Jiangsu Hengrui Pharmaceutical Co., Ltd.) + dexamethasone for the prophylaxis of nausea and vomiting prior to the chemotherapy, and were divided into the experimental group and the control group by whether or not to continue the prophylaxis with o Ondansetron Oral Soluble Pellicles for 5-7 days after the chemotherapy as shown in the figure below.
Study: NCT05141227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-stage Open reduction and internal fixation ( ORIF) using plates & screws
Description: Two stage ORIF using initially temporary spanning fixator then conversion to plates \& screws

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-stage external fixation (EX.FIX.) with minimal internal fixation using cannulated screws if needed
Description: Single stage Ex.Fix. Using illizarov \& minimal fixation of the articular surface using cannulated screws through mini open approaches
Study: NCT06134947

Intervention type: OTHER
Intervention: Echocardiographic examination
Description: Standard 2D echocardiographic evaluation of right ventricle systolic function will be performed as follows:~* Tricuspid annular peak systolic excursion (TAPSE) will be measured by placing M- mode cursor through tricuspid annulus and measuring the amount of longitudinal motion of the annulus at the peak systole in the longitudinal apical 4chamber view, TAPSE \<-2 Z Score is considered abnormal .~* Tricuspid annular peak systolic velocity (TAPSV) by tissue Doppler \<-2 Z Score is considered abnormal.~Through Tissue Doppler Imaging values of right ventricle will be obtained from the apical four -chamber view using a sample volume placed at the lateral corner of the tricuspid annulus. Peak systolic annular velocity (Ś).

Intervention type: OTHER
Intervention: Echocardiographic examination
Description: Standard 2D echocardiographic evaluation of right ventricle systolic function will be performed as follows:~* Tricuspid annular peak systolic excursion (TAPSE) will be measured by placing M- mode cursor through tricuspid annulus and measuring the amount of longitudinal motion of the annulus at the peak systole in the longitudinal apical 4chamber view, TAPSE \<-2 Z Score is considered abnormal .~* Tricuspid annular peak systolic velocity (TAPSV) by tissue Doppler \<-2 Z Score is considered abnormal.~Through Tissue Doppler Imaging values of right ventricle will be obtained from the apical four -chamber view using a sample volume placed at the lateral corner of the tricuspid annulus. Peak systolic annular velocity (Ś).
Study: NCT05261477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bilingual Brain Injury Education and outpatient Navigation for Hispanic families
Description: 1st BIEN was informed by Hispanic parents and clinical providers working with them. It considers their specific needs including lack of familiarity with shared decision models and of knowledge about patient rights and eligibility for community and school services. Based on principles of Social Cognitive Theory, 1st BIEN provides TBI education, teaches problem-solving skills to promote self-efficacy and advocacy; and provides outpatient navigation that allows for observational and experiential learning while supporting access to services in a timely manner. Central to the development of our intervention is the recognition of heterogeneity in individuals' level of readiness to adopt a health behavior according to their level of self-efficacy, expectations, and environment. The 1stBIEN intervention flexibly reduces barriers to access care, and simultaneously improves parental knowledge, health literacy, and self-efficacy to optimize outcomes.
Study: NCT05174533

Intervention type: OTHER
Intervention: Data collection
Description: electrocardiogram
Study: NCT04596995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rozanolixizumab
Description: Study participants receive rozanolixizumab by subcutaneous infusion during the Treatment Period.
Study: NCT06197659

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liberal Fluid Grubu
Description: Patients in this group will be administered 20 mL/kg/h ringer lactate intravenously peroperatively.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Restrictive Fluid Group
Description: Patients in this group will be administered 4 mL/kg/h ringer lactate intravenously peroperatively.
Study: NCT05711277

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard milkshake ONS (Fortisip Compact Protein)
Description: Two 125ml bottles of standard ONS administered a day for two days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High protein, fortified, ice cream
Description: Two 80g servings of N-ICE CREAM administered a day for two days
Study: NCT05271344

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional Products
Description: Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Products
Description: Omega 3 : 1 softgel, 3 x/d Probiotics : 1 caps / d Prebiotics : 1 measuring spoon of powder to be diluted in water, 1x/d Vitamin D : 1 tablet, 2x/d
Study: NCT06130072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iso-amyl- 2-cyanoacrylate.
Description: Hysteroscopic tubal occlusion using iso-amyl- 2-cyanoacrylate in patients with hydrosalpinx prior to IVF

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil
Description: iso-amyl- 2-cyanoacrylate mixed with Ethiodized oil (Lipidol)
Study: NCT05464407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cubitan
Description: 2 bottles of Cubitan daily, for 12 weeks.
Study: NCT05257447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 20 mg Tablet
Description: Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 500 mg Tablet
Description: Single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen 20mg tablet and Chlorzoxazone 500 mg tablet
Description: Concurrent single oral dose given at approximately 8 AM on day of visit, with 6-8 ounces of tap water.
Study: NCT04985695

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural analgesia
Description: All patients received local anesthesia (3-5 ml of 2% Lidocaine). During the preoperative induction of anaesthesia a catheter was inserted 4cm into the epidural space. The catheter will be load during the intervention (0.1 ml/kg/h). In postoperative situation, a patient controlled epidural analgesia was introduced with a debit adapted to the arterial pressure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilateral rectus sheath block
Description: Bilateral rectus sheath block was performed Under general anesthesia and with ultrasound guidance. Rectus sheath block was inserted on each side of the abdomen. All patients received ropivacaine through elastomeric pump

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: A midline sub or supra umbilical laparotomy or xypho-pubian laparotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparotomy
Description: A midline sub or supra umbilical laparotomy or xypho-pubian laparotomy
Study: NCT05427526

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens implantation
Description: Lens surgery during or before vitrectomy surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraocular lens implantation
Description: Lens surgery during or before vitrectomy surgery.
Study: NCT06066151

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Minayo Yeast Drink Product
Description: Participants need to drink one piece of the products each day, for 4 consecutive weeks.
Study: NCT05988242

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Primrose oil
Description: group A will take primrose oil

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender oil
Description: group B will take lavender oil

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placcebo
Description: this is the comparator group who will take the same bottle of oil which dosnt contain the active substances but have the sampe shape, same oder, same color
Study: NCT05600140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing strategy training
Description: Children receive a visual training of viewing strategies (six weeks, 2 times a week, 30 minutes). During the training, children are instructed to use specific viewing strategies (looking in a structured direction which fits the task at hand, zooming in and out / change of visual selective attentional field, visual discrimination). The verbal instructions and exercises are protocol-based. A textbook is used to describe the reactions of the children during training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Viewing strategy training
Description: Children receive a visual training of viewing strategies (six weeks, 2 times a week, 30 minutes). During the training, children are instructed to use specific viewing strategies (looking in a structured direction which fits the task at hand, zooming in and out / change of visual selective attentional field, visual discrimination). The verbal instructions and exercises are protocol-based. A textbook is used to describe the reactions of the children during training.
Study: NCT05633069

Intervention type: OTHER
Intervention: Datas analysed by medical records
Description: Datas analysed by medical records : pupillary parameters: pupillary diameter and pupillary diameter variation. heart rate, the blood pressure, the Behavioral Pain Scale (BPS) pain score before and during painful procedures.~The pupillary parameters were recorded with the AlgiScan® pupillometer (iDMed, Marseille, France), which allows the recording of Pupillary Diameter (PD) variations at the patient's bed at a sampling frequency of 67 hertz.
Study: NCT05478382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 25 MG
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 25 MG
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin 25 MG
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients are given 0 to 3 capsules per administration according to their allocated group.
Study: NCT03450668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mOm incubator
Description: 24 hour usage of test incubator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mOm incubator
Description: 24 hour usage of test incubator

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard incubator
Description: standard incubator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard incubator
Description: standard incubator
Study: NCT04829747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atogepant
Description: Oral Tablet
Study: NCT05736172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain neuroscience grupal education
Description: The face to face education group will be carried out with a physiotherapist addressing various topics in the neurosciences of pain. In the active control group, information will only be provided in written form for the individual patient to read.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain neuroscience grupal education
Description: The face to face education group will be carried out with a physiotherapist addressing various topics in the neurosciences of pain. In the active control group, information will only be provided in written form for the individual patient to read.
Study: NCT05202756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application to Prevent Suicide (MAPS)
Description: Safety Planning Intervention, ecological momentary intervention smartphone app system, and bidirectional communication with study clinician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA Monitoring Only
Description: Safety Planning Intervention; ecological momentary assessment only
Study: NCT06322147

Intervention type: DRUG
Intervention: Doublet or triplet chemotherapy combined with cetuximab
Description: chemotherapy+cetuximab combination therapy，chemotherapy regimens include FOLFOX, FOLFIRI, XELOX, or mFOLFOXIRI.~Cetuximab first dose 400 mg/m2, followed by cetuximab 250 mg/m2 every 2 weeks;~mFOLFOX6: oxaliplatin 85 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h) for up to 12 cycles;~XELOX (biweekly): oxaliplatin 85 mg/m2 (day 1), capecitabine 1000 mg/m2, bid, d1-10;~FOLFIRI: irinotecan 180 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1), and 5-FU 2400 mg/m2 CIV (46 h), Up to 12 cycles;~mFOLFOXIRI: oxaliplatin 85 mg/m2 (day 1), irinotecan 150 mg/m2 (day 1), 5-FU 400 mg/m2 (day 1), LV 400 mg/m2 (day 1) and 5-FU 2400 mg/m2 CIV (46 h).
Study: NCT04908345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Used at induction and during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Used at induction and during surgery
Study: NCT05000905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Attention Training
Description: The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive Attention Training
Description: The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Computer based assessments measuring attention, memory, daily habits, and mental health

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Computer based assessments measuring attention, memory, daily habits, and mental health

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Questionnaires
Description: Computer based assessments measuring attention, memory, daily habits, and mental health
Study: NCT05828836

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol Tablet
Description: allopurinol300mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo once daily
Study: NCT04455022

Intervention type: OTHER
Intervention: Bedside blood culture bottles weighing combined with educational interventions.
Description: Educational actions will be taken to raise the awareness of importance of collecting adequate volume of blood for culture (posters, leaflets and educational activities). The minimum volume will be defined as at least 1 ml. The paramount role of blood culture in process of ruling out newborn sepsis will be emphasized. The sample volume control by using bedside precision scale will be introduced.
Study: NCT06201078

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy
Description: Salvage SBRT will be performed in three subgroups of patients with local recurrence:~Group A - after conventionally fractionated definitive radiotherapy; Group B - after prostatectomy and postoperative radiotherapy; Group C - after ultrahypofractionated definitive SBRT~Target volumes:~GTV- tumour visible on MRI and PET-CT; CTV- 1-3 mm margin around GTV PTV- 3 mm around CTV\*~\*- in cases in which very high accuracy and reproducibility of SBRT are ensured, and the margin overlaps the rectum and/or bladder, it is possible to reduce the margin from these organs to 1 mm.~Dose constrains:~The criteria for limiting the dose in nearby organs are not well-defined for repeated irradiation - the following doses should be aimed:~* Maximum rectal dose ≤103% of the prescribed dose (optimal ≤100%)~* Maximum bladder dose ≤105% of the prescribed dose (optimal ≤103%)~Dose-volume constrains:~Rectum:~• D30% \<15Gy~Bladder:~• D30% \< 15 Gy
Study: NCT05472103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ergonomics surgical workshop
Description: ergonomics surgical workshop
Study: NCT04393311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ulinastatin
Description: Ulinastatin administered via IV infusion (200,000/infusion)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ulinastatin administered via IV infusion
Study: NCT06311370

Intervention type: OTHER
Intervention: Observation
Description: Observed by trained staff and wearing a sensor watch
Study: NCT05763199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHCC
Description: AHCC is the cultured mycelia of Lentinula edodes mushrooms from the Basidiomycetes family.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chemotherapy
Description: Chemotherapy will be administered per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Chemotherapy will be administered per standard of care.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrin